Results 221 to 230 of about 4,413,920 (355)
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti +19 more
wiley +1 more source
Assessing green innovation efficiency and spatial characteristics of China's high tech industry based on the three stage undesirable SBM model. [PDF]
An BW, Xu PY, Liu LZ, Li CB, Guo QP.
europepmc +1 more source
Objective A patient‐centered approach for chronic disease management, including systemic lupus erythematosus (SLE), aligns treatment with patients’ values and preferences, leading to improved outcomes. This paper summarizes how patient experiences, perspectives, and priorities informed the American College of Rheumatology (ACR) 2024 Lupus Nephritis (LN)
Shivani Garg +20 more
wiley +1 more source
ESG ratings empower high-quality development of logistics enterprises through digital transformation and green innovation. [PDF]
Liu D, Sun N, Zhu X.
europepmc +1 more source
Objective Relapsing polychondritis (RP) is a rare disease defined by recurrent cartilaginous inflammation. Anti–collagen II (Col2) antibodies have been proposed as a diagnostic biomarker for RP, but their performance characteristics are not well defined.
Karyssa Stonick +6 more
wiley +1 more source
Retraction notice to "Polluting industries: Does green industrial policy encourage green innovation? Chinese perspective evidence" [Heliyon 10 (2024) e36634]. [PDF]
Yang H, Umair M.
europepmc +1 more source
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier ...
Hermine I. Brunner +14 more
wiley +1 more source
Retraction: Incentive mechanism of multiple green innovation behaviors of equipment manufacturing enterprises: A managers, green coordination groups and employees perspective. [PDF]
PLOS One Editors.
europepmc +1 more source
Objective We evaluated the role of 25‐hydroxyvitamin D (25[OH]D), prednisone, and other risk factors for bone mineral density (BMD) loss and osteoporosis in systemic lupus erythematosus (SLE). Methods We calculated the association between 25(OH)D levels and other potential risk factors and BMD measures (spine T scores) and osteoporosis (defined as a T ...
Nima Madanchi +4 more
wiley +1 more source

